Counts G W
Program in Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.
Rev Infect Dis. 1988 Jan-Feb;10(1):76-91. doi: 10.1093/clinids/10.1.76.
Cefoxitin has become one of the most used parenteral antibiotics in the United States, perhaps because of a broad spectrum of activity, including activity against Bacteroides fragilis, which makes the drug suitable for prevention and treatment of intraabdominal and pelvic infections. This review focuses on the use of cefoxitin in obstetric and gynecologic infections, with comparisons to older and newer antibiotics. Numerous studies have shown that cefoxitin is clearly effective; in most of these studies, however, either the initial infection rates were low or the sample sizes were small--circumstances making it difficult to establish the superiority of any one agent. Thus, the necessity of using a drug with activity against B. fragilis for prevention and treatment of pelvic infections has not been proven. Several antibiotics without such activity have been equally effective. Cefoxitin may be of particular value when combined with surgical drainage of pelvic abscesses, infections in which control of B. fragilis may be especially important to outcome.
头孢西丁已成为美国使用最广泛的肠外抗生素之一,这可能是由于其具有广泛的抗菌活性,包括对脆弱拟杆菌的活性,这使得该药物适用于预防和治疗腹腔内和盆腔感染。本综述重点关注头孢西丁在妇产科感染中的应用,并与新旧抗生素进行比较。大量研究表明头孢西丁明显有效;然而,在这些研究中的大多数中,要么初始感染率较低,要么样本量较小——在这种情况下,很难确定任何一种药物的优越性。因此,使用对脆弱拟杆菌有活性的药物来预防和治疗盆腔感染的必要性尚未得到证实。几种没有这种活性的抗生素同样有效。当与盆腔脓肿的手术引流相结合时,头孢西丁可能具有特殊价值,在这类感染中,控制脆弱拟杆菌对治疗结果可能尤为重要。